Shilpa Kshatriya, MD
Cardiovascular Disease · Wichita, KSNPI 1144470063
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,038 of the $5,741 with a category attached, or 70.3%. 22 manufacturers reported payments, led by Kiniksa Pharmaceuticals, Ltd. at 26.8% of the total. Reporting peaked in 2021 at $1,960 and has fallen 57.5% since, to $832 in 2025.
Across 219 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kiniksa Pharmaceuticals, Ltd.$2K
- Medtronic$1K
- Actelion Pharmaceuticals US, Inc.$502
- Abbott$391
- Novartis$357
- Pfizer$328
- plus $2K from 16 others
Across 1 payment — averaging $210.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$210
What the payments were for
- Speaking & faculty fees$1,50026%
- Food & beverage$4,03870%
- Education$2034%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | 4 | $1,537 |
| Medtronic(2 entities) | 25 | $1,039 |
| Actelion Pharmaceuticals US, Inc. | 23 | $502 |
| Abbott | 14 | $391 |
| Novartis | 33 | $357 |
| Pfizer | 19 | $328 |
| E.r. Squibb & Sons, L.L.C. | 28 | $289 |
| AstraZeneca | 5 | $214 |
| Amgen | 12 | $209 |
| Bayer | 11 | $184 |
| Merck | 10 | $166 |
| Johnson & Johnson | 9 | $111 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $98 |
| Boehringer Ingelheim | 4 | $64 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Regeneron Healthcare Solutions, Inc. | 3 | $52 |
| Amarin Pharma, Inc. | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Surmodics, Inc. | 3 | $23 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Boston Scientific | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,741 in reported general payments places this provider in the 75th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 579 | $469,341 |
| VyndamaxTafamidis | 15 | $363,802 |
| XareltoRivaroxaban | 249 | $178,348 |
| EntrestoSacubitril/Valsartan | 208 | $167,424 |
| AdempasRiociguat | 11 | $155,213 |
| CamzyosMavacamten | 15 | $119,557 |
| FarxigaDapagliflozin Propanediol | 63 | $38,182 |
| BrilintaTicagrelor | 42 | $23,099 |
| Ranolazine ErRanolazine | 156 | $16,211 |
| Repatha SureclickEvolocumab | 12 | $11,975 |
| CorlanorIvabradine Hcl | 12 | $8,160 |
| VascepaIcosapent Ethyl | 15 | $6,793 |
| Praluent PenAlirocumab | 13 | $6,227 |
| Potassium Chloride | 257 | $4,723 |
| SotalolSotalol Hcl | 268 | $4,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $328 | $833,144594 claims |
| Johnson & JohnsonXarelto | $111 | $178,348249 claims |
| NovartisEntresto | $357 | $167,424208 claims |
| BayerAdempas | $184 | $155,21311 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $289 | $119,55715 claims |
| AstraZenecaFarxiga, Brilinta | $214 | $61,281105 claims |
| AmgenCorlanor | $209 | $8,16012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Wichita
- Bassem ChehabWichita$482K
- Joseph GalichiaWichita$177K
- Wassim ShaheenWichita$137K
- Layne ReusserWichita$91K
- Aziz MaksoudWichita$81K
- Hossein AmiraniWichita$18K
- Ahmed MohamedWichita$17K
- Daniel AlvarezWichita$16K
- Freidy EidWichita$13K
- Mohamad FarhatWichita$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.